1476 related articles for article (PubMed ID: 19650569)
1. Prevalence and management of hypertension in primary care in Portugal. Insights from the VALSIM study.
Cortez-Dias N; Martins S; Belo A; Fiuza M;
Rev Port Cardiol; 2009 May; 28(5):499-523. PubMed ID: 19650569
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome in Portugal: prevalence and implications for cardiovascular risk--results from the VALSIM Study.
Fiuza M; Cortez-Dias N; Martins S; Belo A;
Rev Port Cardiol; 2008 Dec; 27(12):1495-529. PubMed ID: 19280993
[TBL] [Abstract][Full Text] [Related]
3. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, management and control of diabetes mellitus and associated risk factors in primary health care in Portugal.
Cortez-Dias N; Martins S; Belo A; Fiuza M;
Rev Port Cardiol; 2010 Apr; 29(4):509-37. PubMed ID: 20734573
[TBL] [Abstract][Full Text] [Related]
5. Current status of antihypertensive prescription and associated blood pressure control in Japan.
Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
[TBL] [Abstract][Full Text] [Related]
6. Anti-hypertensive drug utilization in Continental Portugal (1999-2004).
Furtado C; Pinto M
Rev Port Cardiol; 2006 Mar; 25(3):273-92. PubMed ID: 16789402
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
8. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004.
Gu Q; Burt VL; Paulose-Ram R; Dillon CF
Am J Hypertens; 2008 Jul; 21(7):789-98. PubMed ID: 18451806
[TBL] [Abstract][Full Text] [Related]
10. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
Neutel JM
Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive drug prescription trends at the primary health care centres in Bahrain.
Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):219-27. PubMed ID: 11501335
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
13. Patient satisfaction with antihypertensive therapy.
Chen K; Chiou CF; Plauschinat CA; Frech F; Harper A; Dubois R
J Hum Hypertens; 2005 Oct; 19(10):793-9. PubMed ID: 15951740
[TBL] [Abstract][Full Text] [Related]
14. Uptake of angiotensin II receptor blockers in the treatment of hypertension.
Greving JP; Denig P; van der Veen WJ; Beltman FW; Sturkenboom MC; de Zeeuw D; Haaijer-Ruskamp FM
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):461-6. PubMed ID: 15912393
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment.
Pikilidou MI; Lasaridis AN; Sarafidis PA; Tziolas IM; Zebekakis PE; Dombros NV; Giannoulis E
Clin Exp Hypertens; 2007 Nov; 29(8):563-73. PubMed ID: 18058481
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive persistence and drug class.
Marentette MA; Gerth WC; Billings DK; Zarnke KB
Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence, treatment and control of hypertension in family practice patients in France during 1994].
Poggi L; Chamontin B; Lang T; Menard J; Chevalier H; Gallois H; Cremier O
Arch Mal Coeur Vaiss; 1996 Aug; 89(8):1075-80. PubMed ID: 8949382
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, awareness, treatment and control of hypertension in Portugal. The PAP study.
De Macedo ME; Lima MJ; Silva AO; Alcântara P; Ramalhinho V; Carmona J
Rev Port Cardiol; 2007 Jan; 26(1):21-39. PubMed ID: 17427834
[TBL] [Abstract][Full Text] [Related]
20. [Inadequate treatment and control of arterial hypertension in patients with type 2 diabetes mellitus].
Boero R; Prodi E; Borsa S; Berti V; Fiorio E; Ferraro L; Massara C; Quarello F
G Ital Nefrol; 2002; 19(4):413-8. PubMed ID: 12369043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
